TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

OMEPRAZOLE

OMEPRAZOLE Proton Pump Inhibitors
Cardiovascular Approved 2002-07-31
22
Indications
--
Phase 3 Trials
23
Years on Market

Details

Status
Prescription
First Approved
2002-07-31
Routes
ORAL
Dosage Forms
CAPSULE, DELAYED REL PELLETS, TABLET, DELAYED RELEASE, TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE

OMEPRAZOLE Approval History

Loading approval history...

What OMEPRAZOLE Treats

1 indications

OMEPRAZOLE is approved for 1 conditions since its original approval in 2002. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Heartburn
Source: FDA Label
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

OMEPRAZOLE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Use(s) treats frequent heartburn (occurs 2 or more days a week) not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect

OMEPRAZOLE Patents & Exclusivity

Latest Patent: Dec 2036

Patents (2 active)

US10835488 Expires Dec 8, 2036
US10076494 Expires Dec 8, 2036
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.